Insmed Investor Relations Material
Latest events
Q4 2023
Insmed
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Insmed Incorporated
Access all reports
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.
Key slides for Insmed Incorporated
Q4 2023
Insmed Incorporated
Q4 2023
Insmed Incorporated
Latest articles
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Ticker symbol
Country
đșđž United States